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ABSTRACT 
Objectives: To estimate the incidence, prevalence and mortality of 
Granulomatosis with polyangiitis (GPA) in the United Kingdom. 
Methods: We conducted a historical cohort study using data from the Clinical 
Practice Research Datalink and Hospital Episode Statistics (CPRD-HES). We 
calculated incidence rate ratios, adjusted for age, gender and ethnicity, using 
Poisson regression. 
Results: We identified 462 cases diagnosed between 1997 and 2013. Our 
overall estimate of incidence was 11.8 (95% CI 10.7-12.9)/million person-years. 
Incidence in children (aged <16 years) was 0.88 (95% CI 0.40-1.96), and adults 
14.0 (95% CI 12.8-15.4). The incidence was lower in females (adjusted IRR 
0.68; 95% CI 0.56-0.81) and highest in the 55-69 year age-group (adjusted IRR 
9.5, 95% CI 6.9-13.0; reference group 0-39 years). Incidence was not 
significantly different in the Black / Minority Ethnic population compared to the 
white population (adjusted odds ratio 0.78, 95% CI 0.53-1.13, p=0.13). The 
prevalence in 2013 was 134.9 (121.3-149.6) /million. Mortality was 13.6% at 1-
year, and higher in HES than CPRD-identified cases (Hazard ratio 3.16, 95% CI 
2.19-4.56, p<0.001). 
Conclusions:  
By combining primary and secondary care datasets we have found the incidence 
and mortality of granulomatosis with polyangiitis to be higher than previously 
reported. We predict that at present each year in the UK there will be 
approximately 700 new cases of whom 95 will die within 12 months. 
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INTRODUCTION 
Previous estimates of incidence and prevalence of Granulomatosis with 
polyangiitis (GPA, formerly known as Wegener’s granulomatosis) vary widely and 
have mainly been from small studies with low numbers of cases.[1] In addition, 
there are few data on influence of ethnic group, gender and age on incidence. 
To improve the evidence base, a large study is needed that captures the full 
spectrum of people with this illness. Studies of disease incidence based on 
hospital case series in specialist centres may miss the mildest and most severe 
cases, as they may never be referred to the specialist centre, or may die before 
referral can be arranged. Studies based in primary care have the potential to 
reduce such referral bias, but may miss the most severe cases that are 
diagnosed in hospital and die before accessing primary care services again. 
Ideally, a cohort is needed with case ascertainment in both primary and 
secondary care. 
The aim of this study is to estimate the incidence, prevalence and mortality of 
Granulomatosis with polyangiitis in a UK population-based cohort, using both GP 
and hospital records contained within the CPRD and HES datasets, during 1997-
2013. 
PATIENTS AND METHODS 
Study design and study population 
This is a historical cohort study containing the 398 practices in the CPRD with 
data linked to HES (approximately 65% of patients in the whole CPRD). 
The CPRD is a longitudinal database of anonymised medical records from general 
practitioners. Patients are broadly representative of the UK population in terms 
of age, sex and ethnicity.[2] HES contains records of all inpatient stays and day 
case attendances in England. Primary and secondary diagnoses from each 
admission are coded using ICD-10. 
We included people contributing data to CPRD-HES between 1 April 1997 and 31 
December 2013. Patients were eligible for periods of time where their CPRD 
records were deemed to be of acceptable standard for research by the CPRD.[2] 
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Case definition 
Cases had a diagnosis of Granulomatosis with polyangiitis by either Read code in 
the CPRD or ICD-10 code in HES. To select relevant diagnosis codes, the Read 
code and ICD-10 dictionaries were searched using the terms “Granulomatosis 
with polyangiitis” and the condition’s former name “Wegener’s Granulomatosis”. 
This identified only one relevant and specific code in each: Read code G754, and 
ICD-10 code M31.3, both for “Wegener’s granulomatosis”. The Read code has 
previously been validated[3], and work had previously been undertaken locally 
to validate the ICD-10 code as described in the discussion. The diagnosis date 
was taken as first occurrence of a code for ‘Vasculitis’ or ‘Granulomatosis with 
polyangiitis’, in a patient with a CPRD or ICD-10 code for Granulomatosis with 
polyangiitis, as we considered it unlikely that two types of vasculitis would co-
exist in the same person. Incident cases had a first record of a code for 
Granulomatosis with polyangiitis during the study period, and included only 
patients with at least 1 year of follow up from practice registration prior to 
diagnosis to try to minimise the number of prevalent cases misclassified as 
incident[4]. 
The denominator was all the people who contributed research standard data to 
the CPRD-HES during the study dates.[2] 
Statistical analysis 
We categorised age into groups (0-15 years, 16-39 years, 40-54 years, 55-69 
years, 70-84 years, 85+ years). Self-reported ethnicity was coded according to 
the Office for National Statistics 5+1 categories (White, Mixed, Asian, Black, 
Chinese or other, and unknown). In addition, to improve statistical power, we 
recoded ethnicity as white vs Black and Minority Ethnic (BME) vs unknown. We 
also performed a sensitivity analysis by re-categorising those with unknown 
ethnicity as white. 
We calculated crude annual incidence rates /million person-years, and stratified 
these by age group, sex and ethnic group. Unadjusted incidence rate ratios 
(IRR) were obtained by fitting variables individually in separate Poisson 
regression models. Mutually adjusted IRRs were obtained by fitting age, sex and 
ethnic group as a priori confounders in a single Poisson model. 
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We calculated point prevalence /million people on 1 July 2013 and stratified this 
in the same way as for incidence. We used logistic regression to calculate odds 
ratios. 
We used Kaplan-Meier methods to estimate survival in patients with 
Granulomatosis with polyangiitis at pre-specified times following diagnosis (30-
days, 90 days and 1-year) and stratified mortality rates by source of case 
identification (CPRD with or without a HES diagnosis vs. identified by HES only), 
age, sex and ethnicity. We used Cox proportional hazards models to compare 
hazard ratios. 
We used direct standardization of CPRD/HES age and sex specific incidence rates 
to the age and sex-stratified UK population in 2016, [5] to estimate the number 
of expected incident cases in the UK, and applied our mortality estimate to 
predict how many would die within 12 months. We estimated prevalence from 
the total population of the UK in 2016. 
All analyses were performed using Stata 14 statistical software (Statacorp, 
Texas, USA). 
For purposes of comparison with the previous CPRD study,[3] we re-ran our 
analyses using CPRD-only data (the whole of the CPRD including those people 
from practices without linked HES data) which we report in a sensitivity analysis. 
Ethics 
Independent Scientific Advisory Committee (ISAC) for MHRA Database Research 
approval was obtained for this study on 21/07/2015 (protocol 15_150R). 
RESULTS IN CPRD-HES 
Overall, we identified 462 incident cases of Granulomatosis with polyangiitis in 
CPRD-HES (see figure 1). The cohort had a slight male predominance (56.7% 
male) and mean age at diagnosis 60.0 (SD 15.9) years. 
Incidence: 
We estimated the overall incidence rate to be 11.8 (10.7-12.9) /million person-
years based on 462 cases of Granulomatosis with polyangiitis in 39,286,088 
person-years of follow up. The incidence in children (aged <16 years) was 0.88 
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(95% CI 0.40-1.96)/million person-years, and among adults (≥16 years) was 
14.0 (95% CI 12.8-15.4)/million person-years. 
Temporal trend: 
The incidence by year is shown in table 1. The annual incidence in CPRD-HES 
appears to increase during the first few years of the study period but there was 
no significant change from 2000 onwards (IRR /year 1.02, 95% CI 0.99-1.04, p-
trend=0.2). 
Age, Gender: 
Crude incidence rates and adjusted rate ratios are presented in table 2. 
Incidence was lower among women than men with adjusted IRR 0.67 (95% CI 
0.56-0.81, p<0.001). Peak age of incidence was at 55-69 years (IRR 6.8, 95% 
CI 4.9-9.6, p<0.001, compared with 16-39 years) and similar at 70-84 years 
(IRR 6.4, 95% CI 4.5-9.1, p<0.001, compared with 16-39 years). 
Ethnicity 
We identified ethnicity for 90.7% of cases of Granulomatosis with polyangiitis, 
but only 76.8% of the denominator CPRD-HES linked population (see online 
supplementary table A). The ‘unknown’ denominator population was half as large 
as the white population, and 3 times the size of the BME population. Crude 
incidence was highest in the white ethnic group (16.2, 95% CI 14.7-17.9) 
/million person-years, intermediate in the BME group (7.9, 95% CI 5.5-11.3) 
and lowest in the group with unknown ethnicity (3.7, 95% CI 2.8-5.0). In 
analysis adjusted for age and sex, the results were similar but slightly 
attenuated: the incidence rate ratio for BME compared to whites was 0.64 (95% 
CI 0.44-0.94) and for people of unknown ethnicity compared to whites was 0.30 
(95% CI 0.22-0.41). 
In the sensitivity analysis, people of unknown ethnicity were re-categorised as 
white. There was a lower incidence in the BME compared to white populations in 
crude incidence (IRR0.64, 95% CI 0.44-0.94, p=0.01) but this was partly 
explained by the younger age-structure of the BME population, and once 
adjusted for age and sex the effect was reduced and non-significant at the 5% 
level (IRR 0.81, 95% CI 0.56-1.18, p=0.3)(Table 2). 
Prevalence 
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In 2013, the prevalence the overall prevalence was 134.9 (95% CI 121.3-
149.6). The prevalence among adults was 163.8 (95% CI 147.2-181.7) /million 
and among children (age <16 years) was 4.2 (95% CI 0.5-15.0) (table 3). In 
analysis mutually adjusted for age, sex and ethnicity, prevalence was lower 
among women than men (OR 0.79, 95% CI 0.64-0.97, p=0.027), highest in the 
70-84 age-group (OR 8.5, 95% CI 5.7-12.5 compared to the 16-39 age-group, 
p<0.0001), and lower in the BME than white population (OR 0.57, 95% CI 0.39-
0.84, p=0.002). 
Mortality 
120 of 462 patients died in 2049 years of follow up giving a mortality rate of 
58.6 /1000 person-years (table 4). Mortality was 4.8% (95%CI 3.2-7.2%) at 
30-days, 9.9% (95%CI 7.5-13.0%) at 90-days, and 13.6% (95%CI 10.8-
17.2%) at 1-year. Mortality was similar in males and females (Hazard ratio (HR) 
0.8, 95% CI 0.6-1.2), higher with increasing age (HR for ≥85-years compared to 
16-39 age-group 16.1, 95% CI 3.6-72.8, p-trend<0.0001). Mortality was 
highest in the group with unknown ethnicity (HR compared to whites 1.8, 95% 
CI 1.1-3.0), intermediate in whites, and appeared lowest in the BME group (HR 
0.5, 95% CI 0.1-2.0) however there were only 2 deaths in this group. Mortality 
was higher in people identified only in HES-only compared with cases identified 
in CPRD with or without a HES diagnosis (HR 2.3, 95% CI 1.6-3.4, p<0.0001). 
This is shown in the Kaplan-Meier survival estimates for people with 
Granulomatosis with polyangiitis presented separately by source of case 
ascertainment which are shown in figure 2. 
Estimated UK incidence 
We estimate that at present each year in the UK there will be 700 new cases of 
Granulomatosis with polyangiitis, of whom 95 will die within 12 months. We 
estimate there are 8750 people living with Granulomatosis with polyangiitis in 
the UK in 2016. 
Sensitivity Analysis (Use of data from all CPRD practices) 
We identified 574 incident cases of Granulomatosis with polyangiitis during 
1995-2014 in the whole CPRD (see online data supplementary figure A). Similar 
to CPRD-HES, there was a slight male predominance (54.9% male), and a 
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similar age at diagnosis (mean 58.6(SD 15.8) years. The estimated incidence 
was lower at 8.1 (95% CI 7.5-8.8) /million person-years. The effect of age and 
gender were similar (see supplementary data tables B&C). The incidence was 
stable throughout the period. The mortality rate was also lower: 125 patients of 
574 died in 3002.2 years of follow up, giving a mortality rate of 41.6 /1000 
person-years with mortality 2.1% at 30-days, 4.0% at 90-days, and 8.5% at 1-
year. 
 DISCUSSION 
Main findings 
Our estimate of the incidence of Granulomatosis with polyangiitis in the UK is 
11.8/million person-years, which is higher than previous estimates. The 
incidence has been stable from 2000 onwards, and is higher in men than women 
and is highest in older age-groups. The incidence was lower in the BME than 
white population in crude analyses, but this was partially explained by the 
different age and sex distribution of the BME population. The prevalence of 
Granulomatosis with polyangiitis was 134.9/ million in 2013, higher in men than 
women, and highest in the 70-85 age-group. Prevalence was lower in BME than 
white people, and this was again partially explained by confounding by age and 
sex. Mortality among people with Granulomatosis with polyangiitis was 14% at 1 
year, and was significantly worse among those identified in hospital than in GP 
records. 
Strengths: 
To our knowledge this is the first study that has combined general-population-
based and hospital case ascertainment. Our comparator analysis with case 
ascertainment from primary care records (CPRD-only) shows that case 
ascertainment using both primary and secondary care is a more sensitive 
method, and that it allows identification of an important group of patients with 
the highest mortality. Compared to case ascertainment only in secondary care, 
this method is also more sensitive, and identifies a group of patient with lower 
mortality. 
To our knowledge, it is one of the largest studies of Granulomatosis with 
polyangiitis ever conducted. The largest studies both report cases identified prior 
to 2000 and identified cases using hospital discharge registers in Sweden 
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(n=1938) and Finland (n=492)[6–8], which are difficult to compare to our study 
as they both report a rising incidence during their study periods, which is at least 
partially explained by increased recognition of the condition due to the 
introduction of routinely available ANCA-testing during the 1990s. The largest 
recent study was the previous CPRD study, which identified 295 incident 
cases,[3] and our analysis of 462 cases has given the analyses greater power, 
allowing estimates such as incidence and prevalence in the paediatric (<16 
years) population. This study is also the first in the CPRD, and second in the UK, 
to include ethnicity, and provide predictions for planning health services for the 
BME population. 
Limitations 
The main limitation of this study is lack of power, which limits all studies of rare 
diseases. However we have used the largest existing database of linked primary 
and secondary care records worldwide. Secondly this study has limitations 
inherent in research using large databases of routinely collected healthcare 
information. In particular, the validity and date of each diagnosis could not be 
verified externally. However, the previous CPRD study examined the anonymised 
letters from 31 patients coded as G754, and the diagnosis of Granulomatosis 
with polyangiitis was confirmed in 28 of those giving a positive predictive value 
(PPV) of 90%[3]. An additional 1 (4%) case had a diagnosis of microscopic 
polyangiitis, and in 2 (7%) the diagnosis could not be confirmed but it was likely 
they had some form of vasculitis. Our previous study using multiple sources of 
case ascertainment to identify incident cases of ANCA-associated vasculitis,[9] 
found searching inpatient discharges using ICD-10 code M313 identified 119 
cases in our local hospital between 2007 and 2013. Of these, review of the 
medical notes confirmed a diagnosis of Granulomatosis with polyangiitis in 102, 
giving a PPV of 86%. A further 10 (8%) cases had a diagnosis of microscopic 
polyangiitis, and only 7 (6%) had no evidence of systemic vasculitis. In both 
instances, the number of missed cases could not be estimated, however we 
would expect that some patients were only ever coded as ‘vasculitis’ and missed 
by our search. It is most likely that our results are an under-estimate of the true 
incidence and prevalence. 
It is also possible that some prevalent cases may have been wrongly identified 
as incident, which would falsely increase our estimate of incidence. However, GP 
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records should record previous significant diagnoses even in new registrations, 
and most relapses are in first year after diagnosis, meaning that we will have 
excluded most prevalent cases from our incidence estimate by requiring one 
year of active follow up prior to diagnosis. This method is the same as used 
previously,[3] and has been validated in a range of other chronic conditions in 
the CPRD.[4] 
Fits in with other literature: 
Overall, our estimate of incidence is higher than in previous studies and we think 
this was due to the more sensitive strategy of case ascertainment. In the last 10 
years in Europe estimates (which are in studies of adults only) have ranged from 
4.9/million adult-years in a hospital-based study in Southern Spain to 
11.3/million adult-years in a hospital-based study in the UK (Norfolk),[6,10–14] 
although it is unclear whether differences in methods of case ascertainment or 
true geographic differences account for the variation. Our incidence in the CPRD-
only population of 8.1 (95% CI 7.5-8.8)/ million person-years was very similar 
to the previous CPRD study conducted 1990-2005 where the incidence was 
estimated to be 8.3 (95% CI 7.5-9.4),[3] and shows how incidence is under-
estimated unless cases are ascertained from secondary as well as primary care. 
Our findings show a lower incidence in women compared to men (which is in 
keeping with many,[3,10–13,15] but not all,[6,16,17] previous smaller studies) 
and confirm the age-group with the highest incidence to be around 60-70 
years.[3,13] 
The incidence rose rapidly in both CPRD and HES databases in the first 5 years 
after inception of each database (1987 in the CPRD and 1997 in HES) – which is 
a finding common to database studies in other conditions and may reflect data 
collection practices.[18] After these times, each database shows a stable 
incidence. We did not find evidence of a cyclical pattern of incidence, which has 
been seen in other studies.[10] 
A recent study has shown that CPRD-HES contain the same ethnic mix as the UK 
in the 2011 census, and that they provide reliable records of self-reported 
ethnicity.[19] Reliability is much higher for white vs BME differentiation than 
between BME ethnic groups, so we treated ethnicity as a binary variable (white 
vs BME) for most analyses. Frequency of ethnicity recording also increased after 
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1 April 2006 when recording ethnicity was introduced to the UK NHS Quality and 
outcomes framework (QOF); however this only accounts for 22 of our 462 
incident cases. We therefore have incomplete ethnicity data; available for 90.7% 
of cases, and only 76.8% of the denominator population. We used a “worst case 
scenario” approach and re-coded the unknown group to white. This approach 
also reflects the 2011 census results, resulting in 86.2% of the denominator 
population being white compared to 85.2% in the 2011 census. We found that 
the incidence was lower in BME compared to whites – but this was not 
statistically significant at the 5% level. This is similar to our findings in a local 
hospital cohort of people with all types of ANCA-associated vasculitis (and 
complete ethnicity data), where the incidence rate ratio adjusted for age and sex 
for BME compared to white people was 0.7, 95% CI 0.3-1.5, p=0.3).[19] 
However, we found the prevalence of Granulomatosis with polyangiitis was lower 
in BME than white populations even after adjustment for age and sex (adjusted 
OR 0.6, p=0.004). It is possible that a survival bias explains our findings if the 
disease is more severe in the BME population, or that we only captured the more 
severe end of the spectrum for this group, however we were unable to analyse 
the mortality rate difference between the White and BME groups, due to small 
numbers as there were only two deaths (among 29 patients) in the BME group. 
If the UK population ages as predicted in the coming years and the age structure 
of the BME and white populations become more similar, we would expect to see 
an increase in the number of incident cases of Granulomatosis with polyangiitis, 
and an increasing proportion from BME ethnic groups. 
Our estimate of mortality at 1-year using CPRD-HES is higher than our estimate 
of mortality in the CPRD-only, and as high as reported estimates from hospital 
studies. Increased mortality in cases ascertained from HES compared to CPRD 
has been found in other conditions,[20] which shows the importance of 
ascertaining cases from secondary care data in addition to GP records, as 
patients ascertained in hospital are more likely to be sicker. The lowest reported 
1-year mortality of 1-7% comes from registry studies, or highly selective 
(tertiary-referral) centres,[21,22] where patients also have the lowest average 
age. An intermediate level of 5-11% is found in community studies.[12,23] And 
the highest mortality of 14-21% is reported from hospitals, [7,9,24,25] and 
clinical trials of patients with severe disease.[26] The highest mortality is in the 
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first year after diagnosis, and we did not find a bimodal increase in mortality 
after 8 years as reported by Luqmani and colleagues.[23] A recent systematic 
review of mortality confirms ANCA-associated vasculitis has the highest mortality 
of the autoimmune rheumatic conditions.[27] 
Conclusion 
Our findings suggest that incidence of Granulomatosis with polyangiitis is stable 
over time, higher in men than women, and highest in older people. We estimate 
700 incident cases in the UK during 2016. Despite improvements in medical care 
mortality is high, and higher than in other autoimmune rheumatic conditions. We 
predict 95 people in the UK will die this year within 12 months of their diagnosis. 
Estimates which do not include hospital data will underestimate both incidence 
and mortality. 
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KEY MESSAGES 
 We estimate the incidence of Granulomatosis with polyangiitis in the UK is 
11.8/million person-years. 
 Incidence is similar in Black/Minority Ethnic and White populations, but 
prevalence remains lower in BME. 
 Mortality among people with Granulomatosis with polyangiitis is 14% at 1 
year. 
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Table 1: Annual incidence of Granulomatosis with Polyangiitis 1997-2013 per million person-years 
Year Person- years Incident cases Incidence rate (95% CI) 
1997 871999 8 9.2 (4.6-18.3) 
1998 1269386 6 4.7 (2.1-10.5) 
1999 1580708 11 7.0 (3.9-12.6) 
2000 1959570 20 10.2 (6.6-15.8) 
2001 2152646 18 8.4 (5.3-13.3) 
2002 2359964 27 11.4 (7.8-16.7) 
2003 2464465 33 13.4 (9.5-18.8) 
2004 2548038 23 9.0 (6.0-13.6) 
2005 2625711 34 12.9 (9.3-18.1) 
2006 2684390 33 12.3 (8.7-17.3) 
2007 2747254 38 13.8 (10.1-19.0) 
2008 2776129 39 14.0 (10.3-19.2) 
2009 2801004 42 15.0 (11.1-20.3) 
2010 2760640 38 13.8 (10.0-18.9) 
2011 2674883 33 12.3 (8.8-17.4) 
2012 2602133 29 11.1 (7.7-16.0) 
2013 2408704 30 12.5 (8.7-17.8) 
Legend: cases ascertained from the Clinical Practice Research Datalink and Hospital Episode Statistics (CPRD-HES) 
Overall incidence = 462 cases in 39,286,088 person-years of follow up, giving an incidence rate of 11.8 (95% CI 10.7-12.9) 
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Table 2: Adjusted Incidence of Granulomatosis with Polyangiitis 1997-2013 per million person-years  
 Cases Person-years Crude Incidence rate 
(95% CI) 
Crude  
Rate ratios (95% CI) 
Adjusted Rate 
Ratios1 (95% CI) 
p value2  
Overall 462 39,286,088 11.8 (10.7-12.9)     
Sex        
Male 262 19,518,443 13.4 (11.9-15.2) 1 1 <0.0001  
Female 200 19,767,549 10.1 (8.8-11.6) 0.75 (0.62-0.90) 0.67 (0.56-0.81)   
Age group (years)        
Age 0-15 6 6,812,383 0.9 (0.4-2.0) 0.2 (0.1-0.6) 0.2 (0.1-0.6)   
Age 16-39 42 11,758,023 3.6 (2.6-4.8) 1 1 <0.0001  
Age 40-54 100 8,825,359 11.3 (9.3-13.8) 3.2 (2.2-4.6) 3.1 (2.2-4.4)   
Age 55-69 190 6,875,272 27.6 (24.0-31.9) 7.8 (5.6-10.9) 6.8 (4.9-9.6)   
Age 70-84 112 4,113,670 27.2 (22.6-32.8) 7.6 (5.3-10.9) 6.4 (4.5-9.1)   
Age 85+ 12 901,382 13.3 (7.6-23.4) 3.7 (2.0-7.1) 3.4 (1.8-6.4)   
Ethnicity        
White 390 24,040,059 16.2 (14.7-17.9) 1 1 <0.0001  
BME 29 3,690,640 7.9 (5.5-11.3) 0.48 (0.33-0.70) 0.64 (0.44-0.94)   
Unknown 43 11,555,389 3.7 (2.8-5.0) 0.23 (0.17-0.31) 0.30 (0.22-0.41)   
Sensitivity analysis 1 with all Unknown coded as white 
White 433 35,595,448 12.2 (11.1-13.4) 1 1 0.3  
BME 29 3,690,640 7.9 (5.5-11.3) 0.64 (0.44-0.94) 0.81 (0.56-1.18)   
Legend: cases ascertained from the Clinical Practice Research Datalink and Hospital Episode Statistics (CPRD-HES) 
1 Mutually adjusted for other variables in the model (sex, age group and ethnicity) 
2 From mutually adjusted analysis using the likelihood ratio test
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Table 3: Prevalence of Granulomatosis with Polyangiitis in 2013 per million person-years  
 Cases Denomina
tor 
Crude prevalence Crude Odds 
Ratios (95% CI) 
p value Adjusted 
Odds ratios1 (95% 
CI) 
p value2 
Overall 359 2,661,668 134.9 (121.3-149.6)     
Male 189 1,311,314 144.1(124.3-166.2) 1  1 0.03 
Female 170 1,350,349 125.9 (107.7-146.3) 0.87 (0.71-1.07) 0.201 0.79 (0.64-0.97)  
Age 0-15 2 481,893 4.2 (0.50-15.0) 0.1 (0.02-0.4) 0.002 0.1 (0.02-0.4)  
Age 16-39 33 811,940 40.6 (28.0-57.1) 1  1  
Age 40-54 83 583,600 142.2 (113.3-176.3) 3.5 (2.3-5.2) <0.001  3.4 (2.3-5.2)  
Age 55-69 121 453,300 266.9 (221.5-318.9) 6.6 (4.5-9.7) <0.001 6.1 (4.2-9.0) <0.0001 
Age 70-84 106 262,348 404.0 (330.8-488.7) 9.9 (6.7-14.7) <0.001  8.5 (5.7-12.5)  
Age 85+ 14 68,587 204.1 (111.6-342.5) 5.0 (2.7-9.4) <0.001  4.2 (2.2-7.8)  
White 310 1,681,714 184.3 (164.4-206.0) 1  1 <0.0001 
BME 29 457,887 63.3 (42.4-91.0) 0.34 (0.23-0.50) <0.001 0.46 (0.32-0.68)  
Unknown 20 522,067 38.3 (23.4-59.2) 0.21 (0.13-0.33) <0.001 0.22 (0.14-0.35)  
If all unknown ethnicity coded as white: 
White 330 2,203,781 149.7 (134.0-166.8) 1  1  
BME 29 457,887 63.3 (42.4-91.0) 0.42 (0.29-0.62) <0.001 0.57 (0.39-0.84) 0.002 
Legend: cases ascertained from the Clinical Practice Research Datalink and Hospital Episode Statistics (CPRD-HES) 
1 Mutually adjusted for other variables in the model (sex, age group and ethnicity) 
2 From mutually adjusted analysis using the likelihood ratio test
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Table 4: Mortality of Granulomatosis with Polyangiitis 1997-2013 per thousand person-years  
 Cases Deaths Years at risk Crude mortality Crude Odds 
Ratios (95% CI) 
p value Adjusted 
Odds ratios1 (95% CI) 
p value2 
Overall 462 120 2049 58.6     
Male 262 76 1137 66.9 1  1  
Female 200 44 912 48.2 0.7 (0.5-1.1) 0.12 0.8 (0.6-1.2) 0.7 
Age 0-15 6 0 16 0 -  -  
Age 16-39 45 2 156 12.8 1 <0.0001 1 <0.0001 
Age 40-54 114 7 428 16.3 1.3 (0.3-6.5)  1.2 (0.3-5.9)  
Age 55-69 224 36 837 43.0 3.6 (0.9-15.1)  3.3 (0.8-13.8)  
Age 70-84 174 60 551 108.8 9.8 (2.4-40.1)  7.2 (1.7-29.7)  
Age 85+ 30 15 60 249.0 24.4 (5.5-107)  16.1 (3.6-72.8)  
White 390 95 1794 53.0 1 <0.0001 1 0.03 
BME 29 2 115 17.4 0.3 (0.08-1.3)  0.5 (0.1-2.0)  
Unknown 43 23 141 163.2 2.9 (1.8-4.5)  1.8 (1.1-3.0)  
CPRD 319 62 1621 38.2 1  1 <0.0001 
HES-only 143 58 428 135.5 3.1 (2.2-4.5) <0.0001 2.3 (1.6-3.4)  
Legend: cases ascertained from the Clinical Practice Research Datalink and Hospital Episode Statistics (CPRD-HES) 
1 Mutually adjusted for other variables in the model (sex, age group and ethnicity and source of case ascertainment) 
2 From mutually adjusted analysis, using the likelihood ratio test
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Figure 1: Flow diagram of ascertainment of incident cases of granulomatosis 
with polyangiitis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*in order to exclude prevalent cases 
‘acceptable’ patient records and ‘up to standard’ practices are quality standards 
for research devised by the CPRD 
Eligible for linkage to HES 
(n=1220) 
Patient records identified using 
Readcode G754 in CPRD, and 
ICD-10 code M313 in HES 
(n=1762) 
Not eligible for linkage to HES 
(n=542) 
Data deemed of acceptable 
standard by CPRD 
(n=1155) 
Data deemed not of acceptable 
standard by CPRD 
(n=65) 
Under current follow up in an ‘up 
to standard’ (uts) practice at the 
time of diagnosis 
(n=567) 
Startdate of uts data after 
diagnosis (n=412) 
Enddate of uts data before 
diagnosis (n=176) 
Diagnosed between 1 April 1997 & 
31 December 2013 
(n=513) 
Diagnosis before inclusion dates 
(n=40) 
Diagnosis after inclusion dates 
(n=14) 
At least 1 year uts follow up prior 
to diagnosis* 
(n=462) 
Less than 1 year uts follow up 
prior to diagnosis 
(n=51) 
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legend: cases ascertained from the Clinical Practice Research Datalink and 
Hospital Episode Statistics (CPRD-HES) 
 
Figure 2: Kaplan-Meier survival curve for Granulomatosis with Polyangiitis in the 
Clinical Practice Research Datalink (CPRD) 
 
legend: Hazard ratio 3.21 (95% CI 2.23-4.64), p<0.001 (Schoenfeld’s test to 
detect departure from non-proportional hazards; p=0.32) 
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